BC
CSTL icon

Bridgefront Capital’s Castle Biosciences CSTL Stock Holding History

Bridgefront Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,994
Closed -$205K – 648
2021
Q1 		$205K Buy
+2,994
New +$225K 0.06% 579

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $691M AUM 27.96% 1-Year Est. Return

Bridgefront Capital's CSTL Position: Q2 2021 in Review

Bridgefront Capital sold out of Castle Biosciences (CSTL) in Q2 2021, closing a stake of 2,994 shares — an estimated $205K sold.

Bridgefront Capital first reported a position in CSTL in Q1 2021 and held it in 1 quarter. The position peaked at $205K in Q1 2021. 181 funds tracked by Wall St. Rank hold CSTL as of Q2 2021.

  • Bridgefront Capital reported no remaining Castle Biosciences position as of Q2 2021 after selling out during the quarter.
  • Bridgefront Capital sold 2,994 Castle Biosciences shares in Q2 2021, an estimated $205K.
  • Bridgefront Capital first reported a position in Castle Biosciences in Q1 2021 and held it in 1 quarter.
  • Bridgefront Capital's Castle Biosciences position peaked at $205K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.